SCHEDULE: BlackRock Boosts Stake in Mesa Laboratories to 14.4%
Beneficial Ownership Report
BlackRock, Inc. has reported a significant beneficial ownership stake of 14.4% in Mesa Laboratories Inc., holding 782,950 shares of common stock.
Summary
- BlackRock, Inc. has filed an Amendment No. 9 to Schedule 13G, reporting its beneficial ownership in Mesa Laboratories Inc. /CO/.
- BlackRock, Inc. beneficially owns an aggregate of 782,950 shares of Mesa Laboratories Inc. common stock.
- This ownership represents 14.4% of the class of securities.
- BlackRock holds sole voting power over 773,481 shares and sole dispositive power over 782,950 shares.
- No shared voting or dispositive power is reported.
- The filing indicates that the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
- iShares Core S&P Small-Cap ETF, a BlackRock affiliate, is noted as having an interest of more than five percent of the total outstanding common stock.
- BlackRock Fund Advisors, a subsidiary of BlackRock, Inc., beneficially owns 5% or greater of the outstanding shares of the security class.
Sentiment
Score: 7
Explanation: The sentiment is moderately positive. A large, passive stake by a major institutional investor like BlackRock can be seen as a positive signal for investor confidence in Mesa Laboratories Inc., although the document itself is purely factual and does not contain performance-related information.
Positives
- BlackRock, Inc., a major institutional investor, holds a significant 14.4% stake in Mesa Laboratories Inc., which can be viewed as a vote of confidence in the company's long-term prospects.
- The filing explicitly states that the securities are held in the ordinary course of business and not for the purpose of changing or influencing control, suggesting a passive, investment-oriented holding.
Negatives
- The Schedule 13G filing itself does not contain information that would typically be categorized as negative financial or operational news for Mesa Laboratories Inc.
Risks
- The document does not detail specific risks related to Mesa Laboratories Inc.'s operations or financial health, as it is a beneficial ownership report.
Future Outlook
The document is a beneficial ownership report and does not provide any forward-looking statements or guidance regarding Mesa Laboratories Inc.'s future performance or strategic outlook.
Management Comments
- "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11." (Certification by Spencer Fleming, Managing Director of BlackRock, Inc.)
Industry Context
This filing indicates a significant institutional investment by BlackRock in Mesa Laboratories Inc., a company operating in the life sciences and industrial quality control sectors. While the filing itself does not provide industry-specific analysis, BlackRock's substantial stake suggests its confidence in the company's position within its niche markets.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Attorney-in-fact | Previous attorneys-in-fact from April 30, 2023 Power of Attorney | Eric Andruczyk, Richard Cundiff, R. Andrew Dickson, III, Spencer Fleming, Laura Hildner, David Maryles, Christopher Meade, Charles Park, James Raby, Daniel Riemer, David Rothenberg, Brenda Schulz | 2025-01-21 | Execution of a new Power of Attorney by BlackRock, Inc., revoking the prior one. |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Internal Policy/Procedure Update | BlackRock, Inc. executed a new Power of Attorney, effective January 21, 2025, which revokes a previous Power of Attorney dated April 30, 2023. This new document appoints specific individuals as attorneys-in-fact for executing and filing various ownership and control-person reporting requirements with governmental and regulatory authorities. | 2025-01-21 | This change streamlines BlackRock's internal processes for compliance with SEC and other regulatory reporting requirements, ensuring authorized individuals can act on behalf of the company for necessary filings. It does not directly impact Mesa Laboratories Inc.'s corporate governance. |
Related Party Transactions
- iShares Core S&P Small-Cap ETF, an affiliate of BlackRock, Inc., is noted to have an interest exceeding five percent of the total outstanding common stock of Mesa Laboratories Inc.
Stakeholder Impact
- Shareholders: BlackRock's significant 14.4% stake may provide a level of stability and confidence, as a large institutional investor is committed to holding a substantial portion of the company's shares.
Key Dates
| Date | Description |
|---|---|
| 2023-04-30 | Previous Power of Attorney date, which was revoked by the new Power of Attorney. |
| 2025-01-21 | Date of execution for the new Power of Attorney by BlackRock, Inc. |
| 2025-06-30 | Date of event which requires the filing of this statement. |
| 2025-07-18 | Signature date of the Schedule 13G filing by Spencer Fleming, Managing Director of BlackRock, Inc. |
Keywords
Mesa Laboratories Inc., BlackRock Inc., Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Equity Stake, SEC Filing, Investment Management
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.